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A novel therapeutic scaffolding system of engineered nanocarriers within a foammatrix for the long-term
and sequential delivery of growth factors is reported. Mesoporous silica nanospheres were ﬁrst function-
alized to have an enlarged mesopore size (12.2 nm) and aminated surface, which was then shelled by a
biopolymer, poly(lactic acid) (PLA) or poly(ethylene glycol) (PEG), via electrospraying. The hybrid nano-
carrier was subsequently combined with collagen to produce foam scaffolds. Bovine serum albumin
(BSA), used as a model protein, was effectively loaded within the enlarged nanospheres. The biopolymer
shell substantially prolonged the release period of BSA (2–3 weeks from shelled nanospheres vs. within
1 week from bare nanospheres), and the release rate was highly dependent on the shell composition
(PEG > PLA). Collagen foam scaffolding of the shelled nanocarrier further slowed down the protein
release, while enabling the incorporation of a rapidly releasing protein, which is effective for sequential
protein delivery. Acidic ﬁbroblast growth factor (aFGF), loaded onto the shelled-nanocarrier scaffolds,
was released over a month at a highly sustainable rate, proﬁling a release pattern similar to that of
BSA. The biological activity of the aFGF was evidenced by the signiﬁcant proliferation of osteoblastic pre-
cursor cells in the aFGF-releasing scaffolds. Furthermore, the aFGF-delivering scaffolds implanted in rat
subcutaneous tissue for 2 weeks showed a substantially enhanced invasion of ﬁbroblasts with a homo-
geneous population. Taken together, it is concluded that the biopolymer encapsulation of mesoporous
nanospheres effectively prolongs the release of growth factors over weeks to a month, providing a nano-
carrier platform for a long-term growth factor delivery. Moreover, the foam scaffolding of the nanocarrier
system is a potential therapeutic three-dimensional matrix for cell culture and tissue engineering.
 2014 Acta Materialia Inc. Published by Elsevier Ltd. This is an open access article under the CCBY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Tissue regeneration is the current most signiﬁcant paradigm
considered to be a next generation medical therapy to recover
tissue functions in damaged and degenerated tissue [1–6].
Among possible tools in regenerative therapy are delivery sys-
tems for therapeutic molecules such as drugs, growth factors
(GFs) and nucleic acids, as well as tissue cells, particularlyprogenitor and/or stem cells. Elegant designs of drug delivery
systems have often shown controllable and sustainable and even
on-demand and target-speciﬁc delivery, signiﬁcantly improving
the cellular functions in repair and regenerative programs
[7–11]. Moreover, three-dimensionally arranged matrices
properly load and scaffold tissue cells, allowing stem cell therapy
as well as ex vivo engineering of tissue-mimicking structure
[12–18]. As many biological molecules are critically involved in
stem cell functions and tissue regeneration processes, controlled
interactions between cells and biological molecules are of special
importance. In this context, three-dimensional (3-D) scaffolds
possessing therapeutic potential are considered an ideal system
to direct the latent potency of stem cells to targeted functions
in tissue repair and regeneration.
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recognized stimulators or regulators involved in stem cell function
and tissue regeneration. There have been a range of delivery
systems for GFs, which include biopolymer nano/microparticles,
dendrimers and inorganic nanocarriers. In the case of proteins,
the size is relatively large (compared with chemical drugs or
genes), and water-based processing conditions are required in
order to preserve the 3-D protein structure safely, and as such,
the hydrophilic carriers are preferred. Relatively long-term release
over weeks to months is highly recommended to provide the
continuous doses required for tissue repair and regeneration
processes. Without a proper delivery system, continuous treatment
at high doses of GFs is indispensable because of their short half-
lives in physiological conditions.
The present study focuses on mesoporous silica nanospheres
(MSN) to load the GFs. MSN, a class of silica-based nanomaterials,
have been shown to be effective carriers for loading various thera-
peutic molecules, including chemical drugs, proteins and genes
[19–25]. Nanoparticle sizes can be tunable in a range of tens to
hundreds of nanometers, an effective size allowing intracellular
penetration. In particular, the mesopore channels present through-
out the nanosphere provide a large space and area to host mole-
cules. Therefore, the size and structure of mesopores are of
special importance in determining the loading efﬁciency. In the
case of GFs, owing to their relatively large size (tens of kilodaltons
in molecular weight), enlarged mesopores of MSN will more effec-
tively incorporate themwithin the mesopore structure. The surface
can also be easily and properly tunable to provide an afﬁnity to the
drug molecules and sometimes allow chemical links with molecu-
lar probes [19]. These characterize MSN as fascinating candidates
for loading GFs.
The delivery of GFs needs to be long term, generally weeks to
months, to achieve satisfactory biological action [3,5,6]. It has been
shown, however, that the release of biomolecules including pro-
teins from MSN is generally completed in days to a week. While
this is also acceptable as sustainable in the case of some types of
drugs, such as antibiotics and anticancers, a more prolonged re-
lease proﬁle is substantially needed for GFs to signiﬁcantly im-
prove their in vivo efﬁcacy in tissue regeneration [1–3,9,11].
Even though GFs are incorporated well within the mesopore chan-
nel and adsorbed on the pore surface, dissociation of GFs and dif-
fusion out through the mesopore channel is likely to occur easily
in a biological ionic medium.
The present authors propose, for the ﬁrst time, a more sus-
tainable release system for GFs incorporated within the mesopore
channel of enlarged-pored MSN (eMSN) by encapsulating the
outer surface in degradable biopolymers, including poly(ethylene
glycol) (PEG) and poly(lactic acid) (PLA). A biopolymer thin layer
was created via electrospraying the MSN-dispersed polymer
dilute solution. The present authors further sought to use the
delivery system for tissue engineering matrices by incorporation
of the nanocarrier within the collagen 3-D foam scaffold. Acidic
ﬁbroblast growth factor (aFGF) was loaded as the model GF,
and the effects of release on the in vitro proliferative potential
of osteoblastic precursor cells as well as on in vivo cell and tissue
invasion were investigated. The design is depicted schematically
in Fig. 1.2. Materials and methods
2.1. Preparation of aminated-MSN with large mesopores
PEG (Mw 350,000), PLA (Mw 40,000), aminopropyltriethoxy si-
lane (APTES), tetraethyl orthosilicate (TEOS), ammonium hydrox-
ide (NH4OH, 28%) and cetyltrimethylammonium bromide (CTAB)were purchased from Sigma-Aldrich, and used as-received. The
eMSN was prepared according to previous work, with slight mod-
iﬁcation [23]. In brief, 4.57 g of CTAB and 0.73 g NaCl used as the
co-template were dissolved in 89.42 g water, 122.03 g ethanol
and 26.16 g NH4OH solution, followed by the addition of 8.4 g
TEOS. The solution was ultrasonicated using a sonoreactor
(20 Hz, 240 W) for 5 min and then stirred at 500 rpm for 20 h at
room temperature to obtain a homogeneous suspension. Solid
nanoparticles were recovered by centrifuging the suspensions at
10,000 rpm. The nanoparticles were washed with 70% ethanol
and acetone. The washed nanoparticles were dried at 60 C over-
night and then calcined at 600 C for 4 h with a heating rate of
1min1. Amine functionalization of the eMSN was preceded using
APTES: 1 g nanoparticles and 1 g APTES were added to 2 ml 0.1 M
HCl in acetone while stirring at 300 rpm for 24 h at room temper-
ature, and then washed with acetone and dried at 60 C for further
use.2.2. Protein/growth factor loading
From a pilot test, the BSA molecules were observed not to be
loaded onto the eMSN without amination, owing to the charge–
charge repulsion. When aminated eMSN were used, a substantial
quantity of BSA molecules could be incorporated. First, a calibra-
tion curve for BSA was obtained, using the Beer–Lambert law
[24]. The BSA concentration range was varied from 50 to
600 lg ml1. The absorbance was read at 280 nm using a UV-vis
spectrophotometer (Libra S22, Biochrom). For the BSA loading test,
the loading time was ﬁrst determined. BSA was dissolved at differ-
ent concentrations in water (0.25, 0.5 and 1 mgml1). Within the
BSA solutions, the aminated eMSN were added at 1 mg, ultrasoni-
cated for 10 s and left for different times (up to 12 h) at 37 C. At
each incubation time, the nanoparticles were centrifuged, and
the upper clear solution was assessed for the remaining quantity
of protein. The results were plotted as a function of the incubation
time, and the saturation point was determined at 3–6 h. The
loading test was performed in ﬁve replicates for each condition
(n = 5).
Based on this, the BSA loading capacity of the nanoparticles
was determined by the adsorption isotherm, i.e. plotting the
BSA quantity loaded within the nanoparticles with respect to
the concentration of protein initially added to the water med-
ium. The BSA loading capacity was plotted according to the
mass balance equation qe = (C0  Ce)  (V/W), where qe (lg mg1)
is the capacity of BSA adhering to the scaffold sample, C0 and Ce
are the initial and equilibrium concentrations of BSA, respec-
tively (lg ml1), V is the volume of solution (ml), and W is
the weight of the scaffold used (mg). After plotting the qe vs.
Ce curves, a modiﬁed Langmuir isotherm model was applied
for curve ﬁtting, according to the equation qe = KCe/(1 + KCe)
[26], where the unknown parameter K (kinetic constant) can
be determined. Data are presented as a percentage of adsorbed
BSA.
Based on the loading results of BSA within the aminated eMSN,
a speciﬁc growth factor aFGF was introduced. The aFGF was pro-
duced from E. coli, as described elsewhere [27]. Then, 10 mg of
aminated eMSN were immersed in 1 lg of aFGF solution in phos-
phate buffered saline (PBS) solution, where the quantity of nano-
particles was enough to load all the aFGF molecules. This is
based on the consideration that aFGF is negatively charged while
smaller in size than BSA, and the quantity of aFGF used was far less
than the BSA that can be maximally loaded within the nanoparti-
cles. The quantity of aFGF used in the loading study was considered
to be effective biologically in further experiments using the
nanocarrier/scaffold system.
Fig. 1. Schematic design of the eMSN@biopolymer nanocarrier system for sustained delivery of GFs as well as the nanocarrier@scaffold combined system for cell culture and
tissue engineering. For the effective loading of large molecule protein GFs, the MSN were engineered to have enlarged mesopores (eMSN, 12.2 nm), and the surface was
aminated to allow afﬁnity adsorption of negatively charged proteins. Two representative biopolymers including PGA and PLA were chosen for coating the GF-loaded eMSN
surface. For this, an electrospraying process was introduced to produce a thin layer of the biopolymer, which is intended to act as a protective layer for slow release of the GFs
loaded inside the pore channels. The GF-loaded nanocarrier system was subsequently combined with 3-D porous scaffold of collagen by a freeze-drying process, to use the
delivery system for cell culture and tissue engineering.
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collagen
The protein-loaded eMSN were coated with a biopolymer layer
via an electrospraying process. PLA or PEG solution was prepared
at a concentration of 0.1% or 0.25% in dichloromethane (for PLA)
or in water (for PEG), where the protein-loaded eMSN were added
at 1% and ultrasonicated for 10 s to produce a homogeneous mix-
ture of biopolymer/protein-loaded eMSN. The mixture was placed
in a syringe and then electrosprayed under a high DC electric ﬁeld
at a ﬁeld strength of 10 kV/10 cm, using a syringe pump operated
at 0.4 ml h1 in a bath. After the electrospraying process, the nano-
particles produced were collected and then dried overnight.
The biopolymer-coated protein-loaded eMSN were incorpo-
rated in collagen to produce a 3-D nanocarrier/scaffold system. A
collagen solution (0.5% w/v collagen in acetic acid) was mixed with
PBS at 1:3 by weight, which was then incubated at 37 C for 24 h to
induce collagen ﬁbril formation. After centrifugation, the collagen
ﬁbril solution was gathered and used to homogenize with the
nanoparticles. The nanoparticles were mixed with the collagen ﬁ-
bril solution at 10 wt.% by vortexing for 30 s, and the solution
was then poured into a cylindrical mold (5 mm diameter  3 mm
high), frozen at 80 C overnight, and freeze-dried for 3 days to
produce a 3-D porous foam structure.2.4. Sample characterization
The microscopic morphology of the samples was observed by
scanning electron microscopy (SEM; S3000H, Hitachi). The meso-
pore structure of the nanoparticle samples was examined by trans-
mission electron microscopy (TEM; JEM-3010, JEOL). The samples
for TEM were prepared by dispersing the samples in ethanol and
placing a drop onto a holey Cu/Carbon grid. The pore structure of
the samples was analyzed from the nitrogen gas adsorption/
desorption isotherm at 77 K, using a Quantachrome system (2SI-
MP-9, Quantachrome). The samples were pretreated at 200 C
overnight in a vacuum line. The data were analyzed employing
the Barrett–Joyner–Halenda method and the Halsey equation
[28]. The pore size distribution curve was obtained from an analy-
sis of the adsorption branch of the isotherm, and the pore volume
was calculated from the amount adsorbed at a maximum relative
pressure (P/P0). The surface electrical potential of the nanoparticleswere examined by zeta (f) potential measurements. The f-potential
of the samples was measured with a Zetasizer Nano ZS laser Dopp-
ler electrophoresis instrument (Malvern Instruments, UK). The
samples were dispersed in deionized water at pH 7, and the
f-potential was measured ﬁve times at 25 C with an applied ﬁeld
strength of 20 V cm1 (each measurement being the average of 40
runs). The instrument automatically calculates the electrophoretic
mobility (U) and f-potential, according to the Helmholtz–
Smoluchowsky equation: f = Ug/e, where f is the zeta potential,
U is the electrophoretic mobility, g is the dispersing medium
viscosity, and e is the dielectric constant.2.5. BSA and aFGF release study
First, for the release study of BSA, three different nanocarrier
groups were used: uncoated (eMSN); 0.1% PEG-coated eMSN
(eMSN@01PEG); and 0.1% PLA-coated eMSN (eMSN@01PLA). For
each sample, 25 mg was immersed in 5 ml PBS and then incubated
at 37 C for different periods (from 1 day to 30 days), while slightly
agitating. At each incubation time, the samples were centrifuged,
and an aliquot of the supernatant (3 ml) was assayed using a UV-
vis spectrophotometer at 280 nm to detect the BSA released from
the nanoparticles. At each assay, 3 ml of fresh mediumwas reﬁlled,
and the release test was continued for the next run up to 24 days.
For the case of nanocarrier/scaffold systems, the eMSN@01PLA
combined with collagen scaffold (eMSN@01PLA@Col) was used as
a representative sample group. The scaffold sample (5 mm diame-
ter  3 mm high) was immersed in 10 ml PBS, and then incubated
at 37 C for different periods of up to 26 days, while slightly agitat-
ing. At the predetermined time point, each sample was centrifuged,
and an aliquot of the supernatant (3 ml) was assayed using a UV-
vis spectrophotometer at 280 nm to detect the BSA released from
the nanocarriers/scaffold. At each assay, 3 ml of fresh medium
was reﬁlled, and the release test was continued for the next run
up to 26 days. The BSA-free nanocarrier/scaffolds were also tested
and used as the blank control for accurate detection. Five replicates
were tested for each condition and then averaged (n = 5).
For the case of aFGF, the release pattern from the nanocarrier/
scaffold system was analyzed using an enzyme-linked immunosor-
bant assay (ELISA) kit. The eMSN@PLA@Col system was incubated
in PBS for up to 31 days. Each day, the supernatant was collected,
and the samples were refreshed with PBS. The amount of aFGF
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construction kit (Antigenix America, USA). Five replicates were
tested for each condition and then averaged (n = 5).2.6. Cell culture and proliferation assays
For the biological functional study of the aFGF-loaded nanocar-
rier/scaffold system, the mouse osteoblast precursor cell line
MC3T3-E1 (American Type Culture Collection, USA) was used.
The MC3T3-E1 cells were maintained at 37 C in an atmosphere
of 5% CO2 in alpha minimal essential medium (a-MEM; Gibco,
USA) containing 10% fetal bovine serum (FBS; Gibco) and 1% peni-
cillin–streptomycin (PS; Gibco). The medium was replaced three
times per week, and the cells were passaged at subconﬂuency.
The MC3T3-E1 were seeded on each well of 12-well plates at a
density of 10,000 cells with normal medium (a-MEM with 1% PS
and 10% FBS). The seeded cells were allowed to attach to the well
plate for 12 h, after which the culture medium was immediately
replaced with the starvation medium (a-MEM with 1% PS and 1%
FBS). To investigate the effects of aFGF release from the nanocarri-
er/scaffold systems, an indirect assay was ﬁrst used. For this, test-
ing scaffolds (eMSN@01PLA@Col with aFGF; ‘‘+aFGF’’ or without it;
‘‘aFGF’’) were placed over the well, using cell culture inserts (BD
Biosciences, NJ, USA) to allow indirect contact with the seeded
cells. Moreover, for the direct test, the cells were cultured in direct
contact with the nanocarriers/scaffold sample. The cells were cul-
tured up to 14 days, with culture medium refreshed every 2–
3 days. At each culture period (3, 7 and 14 days), cells were col-
lected, and the cell proliferation levels were assessed using a
CCK-8 cell counting kit (Dojindo Molecular Technologies, Japan)
at an absorbance of 450 nm by the iMark microplate reader (Bio-
Rad, USA). The test was performed in triplicate for each condition
(n = 3).
The morphology of the cells was observed by LSM 700 confocal
laser microscopy (Carl Zeiss, Germany). At each culture period, the
cells were ﬁxed with 4% paraformaldehyde solution and stained
with Alexa Fluor 546 Phalloidin (Molecular Probes, USA) for F-actin
in the cells and 40,6-diamidino-2-phenylindole (Molecular Probes)
for the nucleus.2.7. In vivo tissue responses in rat subcutaneous model
The experimental protocols for the animal study were approved
by the Dankook University Animal Care and Use Committee,
Republic of Korea. For implantation of the biomaterials in subcuta-
neous tissue, male Sprague–Dawley rats weighing 250 mg were
used. Sample groups used were eMSN@01PLA@Col with aFGF load-
ing (‘‘+aFGF’’) or without (‘‘aFGF’’). Each scaffold sample was pre-
pared in a cylindrical form (8 mm diameter  3 mm high) under
sterile conditions. Animals were anesthetized with an intramuscu-
lar dose of 80 mg kg1 ketamine and 10 mg kg1 xylazine. A 5-mm
incision was made in the middle of the back, and two small subcu-
taneous pouches were created with scissors in the back area, later-
ally from the spine in each animal. Two samples were placed per
animal, and the incision was sutured with 4–0 non-absorbable
monoﬁlament suture (Prolene). In total, four animals were used
(four for each group). After recovery from anesthesia, animals were
maintained on a 12 h light/12 h dark schedule and provided stan-
dard pellet food and water ad libitum.
After 2 weeks of implantation, the rats were sacriﬁced. Subcuta-
neous tissues of the samples and surrounding tissues were har-
vested for histological analysis and immediately immersed in
10% neutralized buffered formalin for 24 h at room temperature,
dehydrated in a graded ethanol series, bisected and embedded in
parafﬁn. Histological samples 5 lm thick were prepared using arotary microtome, stained with hematoxylin and eosin, and then
visualized under optical microscopy.
2.8. Statistics
Data are presented as mean ± 1 standard deviation (SD). Stu-
dent’s t-test was carried out to ascertain the statistical signiﬁcance
(p < 0.05) between the test groups.3. Results
3.1. eMSN and protein loading
Typical morphologies of the aminated eMSN with enlarged
mesopore size were examined by TEM, as presented in Fig. 2a
and b. The mesopore areas, in bright contrast, are distributed
throughout the nanoparticles. The f-potential of the as-prepared
eMSNwas32 mV, which changed dramatically to a positive value
of +28 mV in the aminated eMSN (Fig. 2c). From a preliminary
study, it was observed that BSA could only be loaded onto the ami-
nated eMSN, but not onto the as-prepared hydroxyl-surfaced
eMSN. The N2 adsorption/desorption isotherm curve of aminated
eMSN exhibits behavior typical of mesoporous materials
(Fig. 2d). The pore size of the aminated eMSN shows an average
of 12.2 nm (Fig. 2e). Table 1 summarizes the BET results on the
eMSN, including the pore size, surface area and pore volume. After
the loading with BSA, the f-potential also changed to a less positive
value of +11 mV, and the large-sized mesopores in the eMSN were
shown to almost completely disappear (Fig. 2c and e), demonstrat-
ing an effective ﬁlling of the mesopore space by the BSA molecules.
The TEM image of the BSA-loaded eMSN shows the ﬁlling of the
large pores (Fig. 2f), in contrast to the unloaded TEM image. The
BET results on the BSA-loaded eMSN are also summarized in
Table 1.
The loading behavior of BSA onto the aminated eMSN was fur-
ther observed with respect to loading time at various initial quan-
tities of eMSN. The BSA molecules showed a loading saturation
after 3–6 h for all cases, at which the loading amount was
0.23 mg, 0.32 mg and 0.37 mg when the initial eMSN were used
at 0.25 mg, 0.5 mg and 1.0 mg, respectively, illustrating that the
protein loading amount increased as the quantity of eMSN in-
creased (Fig. 3a). Almost complete loading of BSA (0.4 mg) was at-
tained when 1.2–1.8 mg of eMSN was used, resulting in loading
efﬁciency of 22–32% by weight (Fig. 3b). The experimental iso-
therm curve was shown to ﬁt well to the well-known Langmuir
isotherm model (presented as a dotted line), with a kinetic con-
stant determined as 5.8  103 (R2 = 0.98).
3.2. Encapsulating with biopolymer (eMSN@biopolymer) and protein
release
After the electrospraying process to encapsulate eMSN with
biopolymer (PEG or PLA), the samples were examined by SEM
and TEM, as shown in Fig. 4. At 0.1%, nanoparticles were well col-
lected, preserving the spherical morphology and size similar to
those of native eMSN (Fig. 4a). The outer surface of the eMSN
was enclosed by a thin layer of biopolymer PEG (Fig. 4c) or PLA
(Fig. 4e). The thickness was quite uniform and dependent on the
biopolymer composition: 16.2 nm (±5.3 nm) on average for PEG
and 5.2 nm (±2.1 nm) on average for PLA. There was no noticeable
agglomeration among nanoparticles at this biopolymer concentra-
tion. At 0.25%, some particles were not completely separated, but
rather highly networked via the biopolymer (Fig. 4b). The thickness
was signiﬁcantly increased, as revealed by TEM images; 40–50 nm
for PEG (Fig. 4d) and 10–20 nm for PLA (Fig. 4f).
Fig. 2. (a, b) TEM image of aminated eMSN with enlarged pore size (12.2 nm on average). Within the aminated eMSN, a model protein BSA was loaded. (c) f-potential plot,
showing the amination of eMSN dramatically changed the surface potential from highly negative (32 mV) to a positive value (+28 mV), and the BSA loading decreased the
value signiﬁcantly (+11 mV). (d) N2 adsorption/desorption plots and (e) pore size distributions of the aminated eMSN before and after the BSA loading. (f) TEM image of
aminated eMSN after the BSA loading, showing the large pores were almost completely ﬁlled.
Table 1
Summary of BET and f-potential results of the nanoparticle samples; aminated eMSN with and without BSA loading.
Pore size (nm) Pore volume (cm3/g) Surface area (m2/g) Zeta potential (mV)
eMSN (aminated) 12.2 0.57 251 +28 mV
BSA loaded 3.36 0.05 109 +11 mV
Fig. 3. Loading amount of BSA on aminated eMSN: (a) examined with various loading times and initial quantities of eMSN used; (b) plotted with respect to the quantity of
eMSN used at a ﬁxed BSA (0.4 mg). Five replicate samples were used for each condition (n = 5). A curve ﬁt to the experimental data (dotted line in (b)) was carried out using
Langmuir isotherm model.
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carriers were investigated (Fig. 4g). The BSA release from the native
aminated eMSN was shown to complete in almost 8 days, yet with
a relatively sustainable release pattern without exhibiting an ini-
tial burst release. The initial linear release tends to curve with time,
possibly diffusion-dominated at this stage. In contrast, when the
eMSN were coated with biopolymer, the BSA release proﬁles be-
came substantially prolonged, and the patterns exhibited several
stages with different release rates for both biopolymer coatings.
Approximately ﬁve different stages made up the whole releasepattern: for the PEG coating (eMSN@01PEG), 1st initial short lag
for 1 day, 2nd linear release up to 4 days, 3rd highly reduced re-
lease up to 7 days, 4th substantially increased release up to 14 days
and, ﬁnally, 5th reduced release up to 17 days were proﬁled. For
the PLA coating (eMSN@01PLA), the ﬁve different stages of the re-
lease pattern were proﬁled similarly to those observed in
eMSN@01PEG. However, the total release period was much more
sustained, with a ﬁnal release up to 24 days. In particular, the re-
gions with reduced release rates (3rd and 5th region) lasted much
longer than those observed for PEG coating; the last stage lasted as
Fig. 4. (a, b) SEM and (c–f) TEM images of various eMSN@biopolymer nanocarriers
produced by electrospraying of the mixture solutions, where eMSN are dispersed in
either PLA or PEG solutions (at various concentrations of 0.1% or 0.25%): (a, c)
eMSN@01PEG; (e) eMSN@01PLA; (b, d) eMSN@025PEG; (f) eMSN@025PLA. A thin
biopolymer layer covered the whole outer surface of eMSN. (g) BSA release study
from the nanocarriers samples of either bare eMSN or biopolymer-coated eMSN
(eMSN@01PEG and eMSN@01PLA), signifying the effects of the biopolymer layer in
sustaining the release pattern. Five replicate samples were used for each condition
(n = 5).
Fig. 5. (a, b) SEM morphologies of the eMSN@01PLA incorporated within 3-D
collagen scaffolds at different magniﬁcations. (c) Protein release study using the
nanocarrier@collagen scaffold delivery system. A statistical comparison between
eMSN@01PLA and Col/eMSN@01PLA showed signiﬁcant difference at all time
points. For better interpretation of the protein release from the Col/eMSN@01PLA,
other reference groups, including BSA from Col, lysozyme from Col, and BSA from
eMSN, are also presented. A dual protein delivery system using model proteins, BSA
and lysozyme could be proposed with the design of loading BSA within
eMSN@01PLA, which was embedded within the lysozyme-loading collagen scaffold.
Data are represented as mean ± SD from ﬁve replicate samples for each group
(n = 5).
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2–3 weeks noticed in the eMSN@biopolymer system featured a
striking contrast to the case observed for the BSA release from
the native aminated eMSN (7 days), suggesting a novel system
for long-term delivery of proteins.
3.3. 3-D scaffolding with collagen (eMSN@biopolymer@collagen)
For the 3-D scaffold, eMSN@01PLAwas used as the representative
nanocarrier. The morphology of the nanocarrier incorporated within
collagen scaffold is presented in Fig. 5. Scaffoldswithwell-developedmacropore structurewere produced (Fig. 5a). A highermagniﬁcation
of the surface reveals the existence of eMSN@biopolymer nanocarri-
ers embedded within the collagen matrix (Fig. 5b).
Fig. 5c shows the protein release proﬁles observed on each sam-
ple group. When protein (lysozyme or BSA) was loaded directly
within the collagen scaffold, it was released for relatively short
periods, and the release period was slightly longer in lysozyme
(12 days) than in BSA (7 days). But, when the protein was
loaded within the nanocarrier, which was then encapsulated with-
in collagen scaffold, the release rate was signiﬁcantly sustained.
The collagen scaffold embedding the nanocarrier was also shown
to prolong the release of BSA further (compare the BSA release
from nanocarrier vs. nanocarrier@collagen).3.4. Applications of GFs
Based on the BSA release proﬁle, a candidate growth factor aFGF
was applied. As shown in Fig. 6a, the release of the aFGF from the
eMSN@01PLA nanocarrier embedded in collagen scaffold was
monitored over a month. The result shows a proﬁle of a highly sus-
tained rate without an initial burst, and further continual release
up to 31 days. The release pattern is shown to consist of three
stages, with an initial lag up to 3 days, then a further increase
in release rate up to 7 days, and a ﬁnal slow-down in the release
up to a month, proﬁling a pattern similar to that observed previ-
ously in the BSA release, although the 1st and 2nd stages ended
up relatively earlier. Again, the effects of the collagen scaffold
Fig. 6. aFGF was loaded within the eMSN@01PLA nanocarrier, which was embedded in the collagen scaffold (Col/eMSN@01PLA), and the MC3T3-E1 cell proliferation and
in vivo tissue response were investigated to conﬁrm the growth factor delivery function: (a) aFGF release proﬁle measured by ELISA assay kit. Five replicate samples were
used for each condition (n = 5). Cell proliferation assays performed (b) indirectly using inserts, which was set to examine the effects of released aFGF from the
nanocarrier@scaffold, as well as (c) directly on the nanocarrier@scaffold. Stimulation in the aFGF-releasing group (‘‘+aFGF’’) vs. aFGF-absent group (‘‘aFGF’’) was statistically
signiﬁcant (⁄⁄p < 0.01, n = 3). (d) Cell growth morphologies during culture for 3, 7 and 14 days. (e, f) In vivo animal study of the nanocarrier@scaffold systems containing aFGF
(‘‘+aFGF’’) or not (‘‘aFGF’’) in rat subcutaneous tissues for 2 weeks. The boxed images in (e) are enlarged in (f), revealing the presence of cells distributed within the scaffolds.
The black lines specify the scaffold/tissue boundary, and the white line indicates the depth of cell penetration. The phenomenon was general in all the replicated samples for
each group (n = 4).
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of the nanocarrier@scaffold system.
The effects of aFGF release on in vitro cell behavior were exam-
ined, as shown in Fig. 6. The cell proliferation is signiﬁcantly en-
hanced by the inﬂuence of aFGF by the indirect culture method
using inserts (Fig. 6b), conﬁrming the biological activity of the aFGF
released from the nanocarrier@scaffold system. Moreover, cells
cultured in direct contact with the delivery system are also simi-
larly stimulated by the presence of aFGF (Fig. 6c). The SEM images also
show the effects of aFGF delivered from the nanocarrier@scaffold,
as the cells cultured on the aFGF-loaded delivery system spread
and proliferated better (Fig. 6d). While the cells with only nanocar-
rier@scaffold had very limited cytoskeletal processes even up toperiods of 14 days, those with aFGF-loaded proliferated actively
with profound cytoskeletal extensions, covering the surface almost
completely as early as 7 days of culture.
The in vivo performance was investigated in rat subcutaneous
tissue. The histological observation (Fig. 6e) reveals no signiﬁcant
inﬂammatory sign or tissue rejection for both nanocarrier@scaffold
groups, suggesting that normal healing processes are engaged in. In
the group free of aFGF, only a thin surface region was invaded with
ﬁbroblast-like cells without cellular penetration deep into the cen-
tral region of the scaffold (nothing in four replicate samplings).
However, there was substantial invasion of cells in the aFGF-
containing group, where the central region of scaffold was fully
populated with cells, leading to a homogeneous cell population
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difference in the presence of cells between the groups (limited
penetration of cells and their presence at the subsurface region
for –aFGF vs. complete penetration and uniform distribution of
cells throughout for +aFGF).
4. Discussion
This study demonstrated novel therapeutic systems involving
protein-delivering nanospheres and tissue engineering scaffolds.
The mesoporous nanospheres engineered with enlarged pores
and aminated surface were shelled with synthetic polymers and
then incorporated within collagen foam scaffold. It was hypothe-
sized the GFs incorporated within the shelled mesoporous nano-
spheres would be released sustainably over weeks to months,
and the release would be effective in stimulating cellular responses
and tissue formation. The study used aFGF to interpret the slow re-
lease pattern, and thus the therapeutic effects were demonstrated
in terms of cellular proliferation and tissue invasion in a rat subcu-
taneous model.
First, for the production of the GF-delivery system, the authors
sought to enlarge the mesopores of nanospheres, which was en-
abled using NaCl in partial replacement of CTAB (25% NaCal) as
an auxiliary chemical in the micelle formation. Indeed, the addition
of NaCl was shown to play an important role in expanding the size
of micelles, and thus the increased micelles ultimately form the in-
creased mesopore space after removal from the surfactants [29].
While the normal MSN obtained only with CTAB had the pore size
of 3–4 nm, the eMSN showed a pore size as large as 12.2 nm.
Thus, the enlarged pores of nanospheres obtained should allow
the incorporation of large protein molecules. Furthermore, a high
mesoporosity level, including pore volume and surface area, should
provide a space for the incorporation of a large amount of protein
molecules. A model protein, BSA, was chosen, which is compara-
tively large in size among biological proteins, with a molecular
weight of 66 kDa and dimension 14  4  4 nm3 [30]. Theoreti-
cally, the internal pore size (taking an average value of 12.2 nm)
of the eMSN exploited here is considered in part (not always) to
allow protein incorporation within the mesopore structure,
and thus for the case of the target protein, GFs, this mesopore size
is believed to be more effective because it is much smaller than
BSA.
Along with the mesopore size and volume, the surface afﬁnity
of eMSNwith the biomolecules to load is another factor to consider
in the design. As the BSA is negatively charged at neutral pH (with
an isoelectric point of 4.7 in water at 25 C [30]), the surface was
functionalized with amine groups using APTES. In general, the
eMSN are negatively charged owing to the presence of a bunch
of hydroxyl groups, which could not permit BSA loading as a result
of charge–charge repulsion. However, owing to the surface amina-
tion, a substantial quantity of BSA could be loaded, with a loading
efﬁciency as high as 22–32%. This level of loading efﬁciency was
relatively higher compared with normal MSN with small mesopore
size (3–5 nm), as generally observed values were 10–20% [29]. This
fact illustrates the effective role of the enlarged pores, together
with the positively charged surface in taking up a larger number
of BSA molecules within the mesopore structure.
The surface shelling of the eMSN was shown to have a signiﬁ-
cant inﬂuence on the release proﬁle of BSA. While the BSA release
from bare eMSN ended at 8 days, its release from the eMS-
Ns@biopolymer continued up to weeks to a month. With regard
to the release mechanism of the BSA from the eMSN@biopolymer,
both water diffusion and biopolymer layer degradation are consid-
ered to dominate the release proﬁles. In other words, water diffu-
sion through the biopolymer layer and/or within the mesopore
channel will drive the slow diffusion out of the BSA molecules. Inthe course of this process, the degradation and possible breakdown
of the biopolymer layer will allow direct contact of BSA with water,
accelerating the release of BSA through the mesopore channel.
Based on the release pattern, it was hypothesized that the regions
with relatively lower (reduced) release rate (at 1st, 3rd and 5th re-
gion) resulted primarily from the presence of the biopolymer coat-
ing layer. In contrast, the relatively rapidly releasing regions (2nd
and 4th region) were possibly due to the coating degradation and
breakdown. In fact, the release rates in these regions were more
similar to the pattern recorded in BSA release from native eMSN.
While the performance of the slow release of BSA was shown here
using two different biopolymer compositions, other types of bio-
polymers with different degradation rates can be introduced to
control the release proﬁle effectively. Moreover, adjusting the bio-
polymer layer thickness is also another way of modulating the dif-
fusion barrier in the release, which will be an interesting study to
follow in the near future. Taken from the results of BSA release, the
eMSN@biopolymer nanocarrier system is considered to be poten-
tially useful for the delivery of large biomolecules such as proteins,
with long-term performance over weeks to a month, the period
considered effective for the delivery of GFs in tissue regeneration
purpose. Here, the present authors sought to make full use of the
novel nanocarrier as the 3-D scaffolding matrix for cell culture
and tissue engineering.
For this, collagen was introduced to incorporate the eMSN@
biopolymer system, because of its excellent biocompatibility as
the 3-D cell matrix [31–33]. The as-fabricated collagen foam scaf-
fold was highly macroporous after the lyophilization process. In
fact, apart from the pore channel, the swelling behavior of the col-
lagen foam is considered to allow enough pore space for cells to
grow and nutrients to be supplied. As the collagen scaffold can
be processed in water-based mild conditions, therapeutic mole-
cules can also be directly incorporated within and used for the
delivery depot. Along with the biological role of scaffolds for tissue
cells, the collagen matrix encapsulating the nanocarriers is thought
to inﬂuence the release proﬁles of proteins inside the nanocarriers.
In fact, when protein (lysozyme or BSA) was incorporated directly
within the collagen foam, it was shown to release over 7–12 days.
Of note, the release period was observed to be longer in lysozyme
than in BSA, which suggests much stronger ionic bonds formed in
the lysozyme with the collagen matrix, and this fact allows one to
surmise the use of positively charged therapeutic molecules in
conjunction with collagen to prolong the release period. However,
when the protein was incorporated within the nanocarrier, its re-
lease was prolonged over a month and, importantly, the release
pattern was similar to that from the nanocarrier, suggesting that
the collagen scaffold played a role mainly in retarding the release
period for a few days more, but not in altering the release kinetics.
At this point, the present authors propose a dual protein deliv-
ery system using the nanocarrier@collagen, wherein one type of
protein is incorporated directly within the collagen scaffold and
the other is pre-loaded within the nanocarrier. While the former
is intended for the therapeutic action within an initial short period
(GF2, as depicted in Fig. 1), the latter is for more long-term delivery
to elicit prolonged biological activity (GF1, as depicted in Fig. 1). In
fact, collagen, as the major structural protein present in the largest
quantity in human tissue, can hold different types of extracellular
matrix proteins, and has been shown to have a high afﬁnity to
many GFs and thus to load them effectively. As the form is hydro-
gel and thus release of GFs is relatively rapid, positively charged
proteins such as lysozyme and many GFs have been shown to form
quite strong bonds and sometimes to exhibit release over a week
[7,34–36].
After conﬁrming the sustained protein release from the delivery
systems, the present authors next sought to ﬁnd the biological
therapeutic efﬁcacy of the system using aFGF, which has been
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blood vessel formation. As it is a negatively charged protein, the
behavior of loading onto aminated eMSN can be presumed based
on BSA. Having demonstrated again the long-term GF release from
the delivery system, the present authors designed further in vitro
cell study. As aFGF has a great potency in cell proliferation, includ-
ing a range of stem cells, the effects of the aFGF release on the
in vitro proliferation of osteoblastic precursor cell line were exam-
ined. Both indirect and direct culture assays proved that the deliv-
ery system played an effective role in scaffolding tissue cells with
therapeutic activity, mainly with proliferative potential for up to
2 weeks. While the cellular proliferation at this stage almost
reached conﬂuence, prolonged culture is not considered to be as
effective as the current outcome.
Based on this in vitro ﬁnding, the present authors next sought to
ﬁnd the in vivo performance of the aFGF-delivering nanocarri-
er@scaffold system. Scaffolding samples were implanted in a rat
subcutaneous tissue for the same period in vitro (2 weeks). The
period of 2 weeks was chosen to reﬂect the in vitro ﬁndings again
in the in vivo situation, and was also considered proper to gain the
therapeutic effects of aFGF as it is involved in a relatively early
phase of tissue repair, such as cell mitosis and vascularization.
From histological observations, there was substantial invasion of
cells in the aFGF-containing group, where the central region of
scaffold was fully populated with cells, leading to a homogeneous
cell population throughout the pore channels. This is primarily due
to the effect of aFGF in stimulating ﬁbroblasts migration through
the pore channels and their subsequent proliferation during the
implantation period of 2 weeks. The effective cellular invasion
through the scaffold channels is considered of special importance
in the regeneration processes of damaged tissues [37,38], suggest-
ing the efﬁcacy of the nanocarriers@scaffold system delivering
aFGF in the applications of tissue regeneration areas.
Given the performance of aFGF-delivery in vitro with cells, the
delivery system is considered to be useful as a therapeutic scaffold
in the culture of stem cells to secure a large population of cells,
stimulating their growth potential, a prerequisite condition for
effective tissue engineering. Furthermore, the use of other GFs or
different types of therapeutic biomolecules can also be designed
to achieve speciﬁc cell and tissue functions. Even the approach of
dual growth factor delivery is possible within the nanocarri-
er@scaffold system, which remains a further interesting research
area; one promising speciﬁc design is the use of vascular endothe-
lial growth factor (VEGF) as GF2 and bone morphogenetic protein
(BMP) as GF1 to achieve initial VEGF delivery for neoblood vessel
formation and further stimulation of osteogenic development of
cells and bone matrix formation for prolonged periods [39,40]. In
fact, the present study demonstrated the therapeutic activity of
the designed scaffolds using aFGF in vitro and in vivo, which is con-
sidered effective for the relatively early phase of tissue regenera-
tion, and thus the implantation period in the subcutaneous tissue
model was only for 2 weeks. However, the period is considered
not to reﬂect the long-term delivery potential of the current sys-
tem sufﬁciently. Therefore, the use of other GFs such as BMP2
and even the use of BMP2/VEGF dual delivery design might be re-
quired in the bone defect models, where much longer periods of
therapeutic action during the regeneration process would be
necessary.5. Conclusions
A novel GF-delivering nanocarrier was designed by coating the
surface of eMSN with biopolymer (PLA or PEG). Enlarged pores al-
lowed efﬁcient loading of large molecule proteins, and the
enclosed biopolymer thin layer effectively sustained the releaseof the proteins over weeks to a month. Incorporation of the
eMSN@biopolymer nanocarrier within collagen scaffold extended
the application of the delivery system for cell culture in tissue
engineering. The collagen scaffold further delayed the delivery of
protein inside the eMSN. Furthermore, it can be effectively used
to directly load different types of proteins, facilitating nanocarri-
er@collagen for the dual protein release system. The aFGF loaded
within the nanocarrier@collagen showed signiﬁcant stimulation
of osteoblastic cell proliferation, eliciting in vitro biological efﬁcacy
and improved in vivo cellular invasion and population in rat subcu-
taneous tissues. The engineered nanocarrier@collagen system is
considered a potential tissue regenerative therapeutic scaffold,
beneﬁtting from the ability to sustain delivery of GFs and to enable
cell- and tissue-support.
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